CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate
20 janv. 2016 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Jan. 20, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high...